{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:00:24Z","timestamp":1793023224871,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12883-016-0658-4","type":"journal-article","created":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T11:07:42Z","timestamp":1470654462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex"],"prefix":"10.1186","volume":"16","author":[{"given":"Andras","family":"Fogarasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"De Waele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Bartalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiusz","family":"Jozwiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Laforgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Verhelst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borivoj","family":"Petrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Pedespan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Castellana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Gislimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Gyorsok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,8]]},"reference":[{"issue":"13","key":"658_CR1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","volume":"355","author":"PB Crino","year":"2006","unstructured":"Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345\u201356.","journal-title":"N Engl J Med"},{"issue":"9639","key":"658_CR2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","volume":"372","author":"P Curatolo","year":"2008","unstructured":"Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639):657\u201368.","journal-title":"Lancet"},{"key":"658_CR3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/B978-0-444-52891-9.00038-5","volume":"111","author":"P Curatolo","year":"2013","unstructured":"Curatolo P, Maria BL. Tuberous sclerosis. Handb Clin Neurol. 2013;111:323\u201331.","journal-title":"Handb Clin Neurol"},{"issue":"4","key":"658_CR4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus G. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243\u201354.","journal-title":"Pediatr Neurol"},{"issue":"5","key":"658_CR5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-0030-1269906","volume":"41","author":"DN Franz","year":"2010","unstructured":"Franz DN, Bissler JJ, McCormack FX. Tuberous sclerosis complex: neurological, renal and pulmonary manifestations. Neuropediatrics. 2010;41(5):199\u2013208.","journal-title":"Neuropediatrics"},{"issue":"8","key":"658_CR6","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1212\/01.WNL.0000142039.14522.1A","volume":"63","author":"S Goh","year":"2004","unstructured":"Goh S, Butler W, Thiele EA. Subependymal giant cell tumors in tuberous sclerosis complex. Neurology. 2004;63(8):1457\u201361.","journal-title":"Neurology"},{"issue":"6","key":"658_CR7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00301665","volume":"11","author":"M Roszkowski","year":"1995","unstructured":"Roszkowski M, Drabik K, Barszcz S, Jozwiak S. Surgical treatment of intraventricular tumors associated with tuberous sclerosis. Childs Nerv Syst. 1995;11(6):335\u20139.","journal-title":"Childs Nerv Syst"},{"issue":"4","key":"658_CR8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.pediatrneurol.2013.12.004","volume":"50","author":"K Kotulska","year":"2014","unstructured":"Kotulska K, Borkowska J, Roszkowski M, Mandera M, Daszkiewicz P, Drabik K, Jurkiewicz E, Larysz-Brysz M, Nowak K, Grajkowska W, et al. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. Pediatr Neurol. 2014;50(4):307\u201312.","journal-title":"Pediatr Neurol"},{"issue":"3","key":"658_CR9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","volume":"59","author":"DN Franz","year":"2006","unstructured":"Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59(3):490\u20138.","journal-title":"Ann Neurol"},{"issue":"19","key":"658_CR10","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","volume":"363","author":"DA Krueger","year":"2010","unstructured":"Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801\u201311.","journal-title":"N Engl J Med"},{"issue":"9861","key":"658_CR11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125\u201332.","journal-title":"Lancet"},{"key":"658_CR12","unstructured":"Votubia (Everolimus) Summary of Product Characteristics. West Sussex, UK: Novartis Europharm Limited; 2014. [ http:\/\/www.votubia.com\/pdf\/Votubia-SMPC%20for%20website%2002-2015-V1.pdf ]. Accessed 18 June 2015."},{"key":"658_CR13","unstructured":"Afinitor (Everolimus) Tablets for Oral Administration Prescribing Information. New Jersey, NJ: Novartis Pharmaceuticals Corporation; 2014. [ https:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/afinitor.pdf ]. Accessed 18 June 2015."},{"issue":"12","key":"658_CR14","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/088307389801301206","volume":"13","author":"ES Roach","year":"1998","unstructured":"Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol. 1998;13(12):624\u20138.","journal-title":"J Child Neurol"},{"issue":"20","key":"658_CR15","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical A","year":"2013","unstructured":"World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama. 2013;310(20):2191\u20134.","journal-title":"Jama"},{"key":"658_CR16","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. National Institutes of Health, US Department of Health and Human Services; 2009. [ http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf ]. Accessed 18 June 2015."},{"issue":"4","key":"658_CR17","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejpn.2012.12.008","volume":"17","author":"S Jozwiak","year":"2013","unstructured":"Jozwiak S, Nabbout R, Participants of the TSCCMfS, Curatolo P, Epilepsy M. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations. Eur J Paediatr Neurol. 2013;17(4):348\u201352.","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"658_CR18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","volume":"49","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus G. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):255\u201365.","journal-title":"Pediatr Neurol"},{"issue":"6","key":"658_CR19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.pediatrneurol.2013.08.017","volume":"49","author":"J Roth","year":"2013","unstructured":"Roth J, Roach ES, Bartels U, Jozwiak S, Koenig MK, Weiner HL, Franz DN, Wang HZ. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatr Neurol. 2013;49(6):439\u201344.","journal-title":"Pediatr Neurol"},{"issue":"9869","key":"658_CR20","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817\u201324.","journal-title":"Lancet"},{"issue":"12","key":"658_CR21","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00381-013-2170-0","volume":"29","author":"AM Cappellano","year":"2013","unstructured":"Cappellano AM, Senerchia AA, Adolfo F, Paiva PM, Pinho R, Covic A, Cavalheiro S, Saba N. Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex. Childs Nerv Syst. 2013;29(12):2301\u20135.","journal-title":"Childs Nerv Syst"},{"issue":"4","key":"658_CR22","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/1570159X11209040404","volume":"10","author":"P Curatolo","year":"2012","unstructured":"Curatolo P, Moavero R. mTOR Inhibitors in Tuberous Sclerosis Complex. Curr Neuropharmacol. 2012;10(4):404\u201315.","journal-title":"Curr Neuropharmacol"},{"issue":"12","key":"658_CR23","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","volume":"17","author":"DM Davies","year":"2011","unstructured":"Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointon K, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17(12):4071\u201381.","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"658_CR24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pediatrneurol.2012.02.015","volume":"46","author":"MH Kohrman","year":"2012","unstructured":"Kohrman MH. Emerging treatments in the management of tuberous sclerosis complex. Pediatr Neurol. 2012;46(5):267\u201375.","journal-title":"Pediatr Neurol"},{"issue":"5","key":"658_CR25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejpn.2013.03.002","volume":"17","author":"K Kotulska","year":"2013","unstructured":"Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczynski D, Kmiec T, Lojszczyk B, Dunin-Wasowicz D, Jozwiak S. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur J Paediatr Neurol. 2013;17(5):479\u201385.","journal-title":"Eur J Paediatr Neurol"},{"issue":"5","key":"658_CR26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","volume":"74","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol. 2013;74(5):679\u201387.","journal-title":"Ann Neurol"},{"issue":"17","key":"658_CR27","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","volume":"364","author":"FX McCormack","year":"2011","unstructured":"McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595\u2013606.","journal-title":"N Engl J Med"},{"issue":"1","key":"658_CR28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejpn.2012.10.005","volume":"17","author":"S Amin","year":"2013","unstructured":"Amin S, Carter M, Edwards RJ, Pople I, Aquilina K, Merrifield J, Osborne JP, O'Callaghan FJ. The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. Eur J Paediatr Neurol. 2013;17(1):36\u201344.","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"658_CR29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3171\/2013.9.PEDS13193","volume":"13","author":"DH Harter","year":"2014","unstructured":"Harter DH, Bassani L, Rodgers SD, Roth J, Devinsky O, Carlson C, Wisoff JH, Weiner HL. A management strategy for intraventricular subependymal giant cell astrocytomas in tuberous sclerosis complex. J Neurosurg Pediatr. 2014;13(1):21\u20138.","journal-title":"J Neurosurg Pediatr"},{"issue":"13","key":"658_CR30","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","volume":"15","author":"DN Franz","year":"2014","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 2014;15(13):1513\u201320.","journal-title":"Lancet Oncol"},{"issue":"6","key":"658_CR31","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","volume":"80","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Care MM, Agricola K, Tudor C, Mays M, Franz DN. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology. 2013;80(6):574\u201380.","journal-title":"Neurology"},{"issue":"9","key":"658_CR32","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.tem.2010.05.003","volume":"21","author":"J Roa","year":"2010","unstructured":"Roa J, Tena-Sempere M. Energy balance and puberty onset: emerging role of central mTOR signaling. Trends Endocrinol Metabol: TEM. 2010;21(9):519\u201328.","journal-title":"Trends Endocrinol Metabol: TEM"},{"issue":"13","key":"658_CR33","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S1470-2045(14)71101-5","volume":"15","author":"H Northrup","year":"2014","unstructured":"Northrup H. The mTOR inhibitor revolution rolls on. Lancet Oncol. 2014;15(13):1418.","journal-title":"Lancet Oncol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-016-0658-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T20:11:00Z","timestamp":1498335060000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-016-0658-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,8]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["658"],"URL":"https:\/\/doi.org\/10.1186\/s12883-016-0658-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,8]]},"article-number":"126"}}